Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis

Marcia Cruz-Correa, Linda M. Hylind, Jessica Hernandez Marrero, Marianna L. Zahurak, Tracy Murray Stewart, Robert A Casero, Elizabeth A Montgomery, Christine Iacobuzio-Donahue, Lodewijk A. Brosens, G. Johan Offerhaus, Asad Umar, Luz M. Rodriguez, Francis M Giardiello

Research output: Contribution to journalArticle

Abstract

Background & Aims: Familial adenomatous polyposis is an autosomal dominant disorder characterized by the development of hundreds of colorectal adenomas and eventually colorectal cancer. Oral administration of the spice curcumin has been followed by regression of polyps in patients with this disorder. We performed a double-blinded randomized trial to determine the safety and efficacy of curcumin in patients with familial adenomatous polyposis. Methods: This study included 44 patients with familial adenomatous polyposis (18–85 years old) who had not undergone colectomy or had undergone colectomy with ileorectal anastomosis or ileal anal pouches, had at least 5 intestinal adenomatous polyps, and had enrolled in Puerto Rico or the United States from September 2011 through November 2016. Patients were randomly assigned (1:1) to groups given 100% pure curcumin (1,500 mg orally, twice per day) or identical-appearing placebo capsules for 12 months. The number and size of lower gastrointestinal tract polyps were evaluated every 4 months for 1 year. The primary outcome was the number of polyps in the curcumin and placebo groups at 12 months or at the time of withdrawal from the study according to the intention-to-treat principle. Results: After 1 year of treatment, the average rate of compliance was 83% in the curcumin group and 91% in the placebo group. After 12 weeks, there was no significant difference in the mean number of polyps between the placebo group (18.6; 95% CI, 9.3–27.8) and the curcumin group (22.6; 95% CI, 12.1–33.1; P =.58). We found no significant difference in mean polyp size between the curcumin group (2.3 mm; 95% CI, 1.8–2.8) and the placebo group (2.1 mm; 95% CI, 1.5–2.7; P =.76). Adverse events were few, with no significant differences between groups. Conclusions: In a double-blinded randomized trial of patients with familial adenomatous polyposis, we found no difference in the mean number or size of lower intestinal tract adenomas between patients given curcumin 3,000 mg/day and those given placebo for 12 weeks. Clinicaltrials.gov ID NCT00641147.

Original languageEnglish (US)
Pages (from-to)668-673
Number of pages6
JournalGastroenterology
Volume155
Issue number3
DOIs
StatePublished - Sep 1 2018

Fingerprint

Adenomatous Polyposis Coli
Curcumin
Adenoma
Safety
Polyps
Placebos
Colectomy
Therapeutics
Intestinal Polyps
Lower Gastrointestinal Tract
Adenomatous Polyps
Colonic Pouches
Puerto Rico
Spices
Capsules
Oral Administration
Colorectal Neoplasms

Keywords

  • Cancer Prevention
  • Familial Adenomatous Polyposis
  • Herbal
  • Turmeric

ASJC Scopus subject areas

  • Gastroenterology

Cite this

Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. / Cruz-Correa, Marcia; Hylind, Linda M.; Marrero, Jessica Hernandez; Zahurak, Marianna L.; Murray Stewart, Tracy; Casero, Robert A; Montgomery, Elizabeth A; Iacobuzio-Donahue, Christine; Brosens, Lodewijk A.; Offerhaus, G. Johan; Umar, Asad; Rodriguez, Luz M.; Giardiello, Francis M.

In: Gastroenterology, Vol. 155, No. 3, 01.09.2018, p. 668-673.

Research output: Contribution to journalArticle

Cruz-Correa, M, Hylind, LM, Marrero, JH, Zahurak, ML, Murray Stewart, T, Casero, RA, Montgomery, EA, Iacobuzio-Donahue, C, Brosens, LA, Offerhaus, GJ, Umar, A, Rodriguez, LM & Giardiello, FM 2018, 'Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis', Gastroenterology, vol. 155, no. 3, pp. 668-673. https://doi.org/10.1053/j.gastro.2018.05.031
Cruz-Correa, Marcia ; Hylind, Linda M. ; Marrero, Jessica Hernandez ; Zahurak, Marianna L. ; Murray Stewart, Tracy ; Casero, Robert A ; Montgomery, Elizabeth A ; Iacobuzio-Donahue, Christine ; Brosens, Lodewijk A. ; Offerhaus, G. Johan ; Umar, Asad ; Rodriguez, Luz M. ; Giardiello, Francis M. / Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis. In: Gastroenterology. 2018 ; Vol. 155, No. 3. pp. 668-673.
@article{5daa4904220647749bd2c318fd768915,
title = "Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis",
abstract = "Background & Aims: Familial adenomatous polyposis is an autosomal dominant disorder characterized by the development of hundreds of colorectal adenomas and eventually colorectal cancer. Oral administration of the spice curcumin has been followed by regression of polyps in patients with this disorder. We performed a double-blinded randomized trial to determine the safety and efficacy of curcumin in patients with familial adenomatous polyposis. Methods: This study included 44 patients with familial adenomatous polyposis (18–85 years old) who had not undergone colectomy or had undergone colectomy with ileorectal anastomosis or ileal anal pouches, had at least 5 intestinal adenomatous polyps, and had enrolled in Puerto Rico or the United States from September 2011 through November 2016. Patients were randomly assigned (1:1) to groups given 100{\%} pure curcumin (1,500 mg orally, twice per day) or identical-appearing placebo capsules for 12 months. The number and size of lower gastrointestinal tract polyps were evaluated every 4 months for 1 year. The primary outcome was the number of polyps in the curcumin and placebo groups at 12 months or at the time of withdrawal from the study according to the intention-to-treat principle. Results: After 1 year of treatment, the average rate of compliance was 83{\%} in the curcumin group and 91{\%} in the placebo group. After 12 weeks, there was no significant difference in the mean number of polyps between the placebo group (18.6; 95{\%} CI, 9.3–27.8) and the curcumin group (22.6; 95{\%} CI, 12.1–33.1; P =.58). We found no significant difference in mean polyp size between the curcumin group (2.3 mm; 95{\%} CI, 1.8–2.8) and the placebo group (2.1 mm; 95{\%} CI, 1.5–2.7; P =.76). Adverse events were few, with no significant differences between groups. Conclusions: In a double-blinded randomized trial of patients with familial adenomatous polyposis, we found no difference in the mean number or size of lower intestinal tract adenomas between patients given curcumin 3,000 mg/day and those given placebo for 12 weeks. Clinicaltrials.gov ID NCT00641147.",
keywords = "Cancer Prevention, Familial Adenomatous Polyposis, Herbal, Turmeric",
author = "Marcia Cruz-Correa and Hylind, {Linda M.} and Marrero, {Jessica Hernandez} and Zahurak, {Marianna L.} and {Murray Stewart}, Tracy and Casero, {Robert A} and Montgomery, {Elizabeth A} and Christine Iacobuzio-Donahue and Brosens, {Lodewijk A.} and Offerhaus, {G. Johan} and Asad Umar and Rodriguez, {Luz M.} and Giardiello, {Francis M}",
year = "2018",
month = "9",
day = "1",
doi = "10.1053/j.gastro.2018.05.031",
language = "English (US)",
volume = "155",
pages = "668--673",
journal = "Gastroenterology",
issn = "0016-5085",
publisher = "W.B. Saunders Ltd",
number = "3",

}

TY - JOUR

T1 - Efficacy and Safety of Curcumin in Treatment of Intestinal Adenomas in Patients With Familial Adenomatous Polyposis

AU - Cruz-Correa, Marcia

AU - Hylind, Linda M.

AU - Marrero, Jessica Hernandez

AU - Zahurak, Marianna L.

AU - Murray Stewart, Tracy

AU - Casero, Robert A

AU - Montgomery, Elizabeth A

AU - Iacobuzio-Donahue, Christine

AU - Brosens, Lodewijk A.

AU - Offerhaus, G. Johan

AU - Umar, Asad

AU - Rodriguez, Luz M.

AU - Giardiello, Francis M

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Background & Aims: Familial adenomatous polyposis is an autosomal dominant disorder characterized by the development of hundreds of colorectal adenomas and eventually colorectal cancer. Oral administration of the spice curcumin has been followed by regression of polyps in patients with this disorder. We performed a double-blinded randomized trial to determine the safety and efficacy of curcumin in patients with familial adenomatous polyposis. Methods: This study included 44 patients with familial adenomatous polyposis (18–85 years old) who had not undergone colectomy or had undergone colectomy with ileorectal anastomosis or ileal anal pouches, had at least 5 intestinal adenomatous polyps, and had enrolled in Puerto Rico or the United States from September 2011 through November 2016. Patients were randomly assigned (1:1) to groups given 100% pure curcumin (1,500 mg orally, twice per day) or identical-appearing placebo capsules for 12 months. The number and size of lower gastrointestinal tract polyps were evaluated every 4 months for 1 year. The primary outcome was the number of polyps in the curcumin and placebo groups at 12 months or at the time of withdrawal from the study according to the intention-to-treat principle. Results: After 1 year of treatment, the average rate of compliance was 83% in the curcumin group and 91% in the placebo group. After 12 weeks, there was no significant difference in the mean number of polyps between the placebo group (18.6; 95% CI, 9.3–27.8) and the curcumin group (22.6; 95% CI, 12.1–33.1; P =.58). We found no significant difference in mean polyp size between the curcumin group (2.3 mm; 95% CI, 1.8–2.8) and the placebo group (2.1 mm; 95% CI, 1.5–2.7; P =.76). Adverse events were few, with no significant differences between groups. Conclusions: In a double-blinded randomized trial of patients with familial adenomatous polyposis, we found no difference in the mean number or size of lower intestinal tract adenomas between patients given curcumin 3,000 mg/day and those given placebo for 12 weeks. Clinicaltrials.gov ID NCT00641147.

AB - Background & Aims: Familial adenomatous polyposis is an autosomal dominant disorder characterized by the development of hundreds of colorectal adenomas and eventually colorectal cancer. Oral administration of the spice curcumin has been followed by regression of polyps in patients with this disorder. We performed a double-blinded randomized trial to determine the safety and efficacy of curcumin in patients with familial adenomatous polyposis. Methods: This study included 44 patients with familial adenomatous polyposis (18–85 years old) who had not undergone colectomy or had undergone colectomy with ileorectal anastomosis or ileal anal pouches, had at least 5 intestinal adenomatous polyps, and had enrolled in Puerto Rico or the United States from September 2011 through November 2016. Patients were randomly assigned (1:1) to groups given 100% pure curcumin (1,500 mg orally, twice per day) or identical-appearing placebo capsules for 12 months. The number and size of lower gastrointestinal tract polyps were evaluated every 4 months for 1 year. The primary outcome was the number of polyps in the curcumin and placebo groups at 12 months or at the time of withdrawal from the study according to the intention-to-treat principle. Results: After 1 year of treatment, the average rate of compliance was 83% in the curcumin group and 91% in the placebo group. After 12 weeks, there was no significant difference in the mean number of polyps between the placebo group (18.6; 95% CI, 9.3–27.8) and the curcumin group (22.6; 95% CI, 12.1–33.1; P =.58). We found no significant difference in mean polyp size between the curcumin group (2.3 mm; 95% CI, 1.8–2.8) and the placebo group (2.1 mm; 95% CI, 1.5–2.7; P =.76). Adverse events were few, with no significant differences between groups. Conclusions: In a double-blinded randomized trial of patients with familial adenomatous polyposis, we found no difference in the mean number or size of lower intestinal tract adenomas between patients given curcumin 3,000 mg/day and those given placebo for 12 weeks. Clinicaltrials.gov ID NCT00641147.

KW - Cancer Prevention

KW - Familial Adenomatous Polyposis

KW - Herbal

KW - Turmeric

UR - http://www.scopus.com/inward/record.url?scp=85052078419&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85052078419&partnerID=8YFLogxK

U2 - 10.1053/j.gastro.2018.05.031

DO - 10.1053/j.gastro.2018.05.031

M3 - Article

C2 - 29802852

AN - SCOPUS:85052078419

VL - 155

SP - 668

EP - 673

JO - Gastroenterology

JF - Gastroenterology

SN - 0016-5085

IS - 3

ER -